Rating Change
Barclays analysts initiated coverage on Abbott Laboratories (NYSE:ABT) with a rating of Overweight on October 07, 2026.
new coverageNYSE:ABT
Barclays Initiates Coverage on Abbott Laboratories (ABT) with Overweight
Barclays analysts initiated coverage on Abbott Laboratories (NYSE:ABT) with a rating of Overweight on October 07, 2026.
At publication ·
What changed
Abbott Laboratories (NYSE:ABT) · new coverage
- Firm
- Barclays
- Rating
- Overweight
- Price at event
- $98.73
- Market capitalization
- $202.5B
At a glance
Key takeaways
- Barclays initiated Overweight coverage on Abbott Laboratories (ABT) on October 7, 2026, reflecting a positive outlook on the healthcare company.
Market Context
Abbott Laboratories operates in the Healthcare sector. The stock currently trades at $98.73 with a market capitalization of $202.5B. The stock has declined 21.6% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Abbott Laboratories.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Abbott Laboratories
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | Barclays | Overweight | N/A |
| Oct 02, 2026 | Rothschild & Co | Buy | N/A |
| Sep 08, 2026 | TD Cowen | Buy | N/A |
| Aug 25, 2026 | TD Cowen | Buy | N/A |
| Aug 13, 2026 | Wolfe Research | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ABT Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ABT?
A rating of Overweight from Barclays reflects the analyst's outlook on Abbott Laboratories (NYSE:ABT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ABT forecast page.